Cassava Sciences Inc (SAVA)
$23.91
0.26 (1.08%)
SAVA Stock Quote Delayed 30 Minutes
3 Short-Squeeze Stocks to Keep on Your Radar
These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
997.90M
PE Ratio
-66.42
EPS
-0.36
Volume (Avg. Vol.)
135,972
Day's Range
$23.63 - $24.20
52-Week Range
$13.84 - $51.59
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and Cassava Sciences Inc News
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon.
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements.
What the Latest Controversy Really Means for SAVA Stock
Headlines and controversy notwithstanding, consider SAVA stock to be one of the more promising biotech plays out there.
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations.
A New Study Makes Cassava Sciences Stock an Interesting Buy
Making progress with what could ultimately be a breakthrough treatment, consider SAVA stock a great speculative buy, whether now, or on further weakness.
SAVA Stock Alert: Cassava Sciences Extends Trial
SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam.
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity.
How High Can SAVA Stock Go Once the Controversy Clears?
If a reproduced SEC letter concerning Cassava Sciences' clearance is legit, SAVA stock could head much higher.
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target.
Caution! It’s Not Safe to Jump on the SAVA Stock Hype Train.
Rumors and speculation surrounding Cassava Sciences incited a buying frenzy in SAVA stock, but this isn't the time to jump on the hype train.
5 Investors Betting Big on Cassava (SAVA) Stock
SAVA stock received a boost yesterday following news that the SEC had closed its case against the company. Here are its top five investors.
The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher
Shares of SAVA stock are soaring higher after the SEC closed its investigation on Cassava over alleged research manipulation.
What Is Going on With Cassava (SAVA) Stock Today?
SAVA stock remains volatile as speculators place bets on Simufilam, Cassava Sciences's Alzheimer's drug under Phase 3 study.
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Cassava is reaching the end of its study on Simufilam, an Alzheimer's treatment, and a third insider just bought shares of SAVA stock.
Why Is Cassava Sciences (SAVA) Stock Up 20% Today?
SAVA stock is rising on hopes of a buyout, which could also mean optimism for its Alzheimer's test and proposed treatment.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!
